Ionis Pharmaceuticals, Inc.
MODULATORS OF DNM2 EXPRESSION
Last updated:
Abstract:
The present embodiments provide methods, compounds, and compositions useful for inhibiting DNM2 expression, which may be useful for treating, preventing, or ameliorating a disease associated with DNM2.
Status:
Application
Type:
Utility
Filling date:
15 Jan 2019
Issue date:
17 Dec 2020